Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JTC2 | ISIN: FR0011184241 | Ticker-Symbol: A89
Tradegate
06.06.25 | 16:00
3,505 Euro
+1,45 % +0,050
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ADOCIA SAS Chart 1 Jahr
5-Tage-Chart
ADOCIA SAS 5-Tage-Chart
RealtimeGeldBriefZeit
3,4803,51516:35
3,5003,50516:00

Aktuelle News zur ADOCIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.05.ADOCIA Confirms its Eligibility for the PEA-PME Scheme258Regulatory News: Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment...
► Artikel lesen
21.05.ADOCIA Announces its Annual Shareholders' Meeting to be Held on June 11th, 2025 in Paris223Regulatory News: Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment...
► Artikel lesen
15.05.Number of Shares and Voting Rights of ADOCIA as of April 30th, 2025228Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité...
► Artikel lesen
14.05.ADOCIA Reports First Quarter 2025 Financial Results and Provides a Business Update245Cash position of €12.2 million as of March 31, 2025, including €9.7m from the private placement successfully completed in February 2025 Cash runway extended until Q2 2026 Top-line...
► Artikel lesen
30.04.ADOCIA Announces the Release of its Universal Registration Document for the Year 2024232Regulatory News: Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment...
► Artikel lesen
28.04.ADOCIA to Present New Data on AdoShell at Upcoming Scientific Conferences - Showcasing Potential Curative Treatment for Type 1 Diabetes247Presentations demonstrate the potential of AdoShellfor allogenic cell therapy in diabetes without immunosuppression, by delivering pancreatic human islets or iPSCs1 New preclinical data support...
► Artikel lesen
ADOCIA Aktie jetzt für 0€ handeln
17.04.ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update366Cash position of €7.5m (million) as of December 31, 2024, including: €2m received from private placement in March 2024 €9.8m from an equity financing line ("PACEO") with Vester Finance ...
► Artikel lesen
11.04.Number of Shares and Voting Rights of ADOCIA as of March 31st, 2025275Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité...
► Artikel lesen
14.03.Number of Shares and Voting Rights of ADOCIA as of February 28th, 2025275Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité...
► Artikel lesen
28.02.ADOCIA Announces the Settlement-Delivery of its €9.7 Million Private Placement725Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage...
► Artikel lesen
26.02.Adocia raises €9.7 million in private placement, extending cash runway to Q2 20261
26.02.ADOCIA Announces the Successful Completion of a €9.7 Million Private Placement, Extending its Cash Runway to Q2 2026592Capital increase of a total amount of €9.7 million in gross proceeds by issuing a total number of 2,125,000 new shares, each with one share warrant attached, at €4.58 per share Gross Proceeds...
► Artikel lesen
25.02.ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update332Cash position of €7.5 million as of December 31, 2024 BioChaperone Lispro final dosing of Phase 3 triggered a $10 million revenue recognition, and top-line data are expected in mid-2025...
► Artikel lesen
14.02.Number of Shares and Voting Rights of ADOCIA as of January 31st, 2025274Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or...
► Artikel lesen
22.01.ADOCIA Announces Half-Year Report on Adocia's Liquidity Agreement with Kepler Capital Markets420Regulatory News: Under the liquidity agreement entrusted by Adocia (Euronext Paris: FR0011184241 ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on...
► Artikel lesen
17.01.Number of Shares and Voting Rights of ADOCIA as of December 31st, 2024405Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or...
► Artikel lesen
23.12.24ADOCIA Announces Its Participation at Upcoming Investor Conferences in 2025412Regulatory News: Adocia (Euronext Paris: FR0011184241 ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions...
► Artikel lesen
19.12.24ADOCIA Announces its Financial Calendar for 2025366Regulatory News: Adocia (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment...
► Artikel lesen
12.12.24ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone Lispro, Milestone Associated with a $10 Million Payment495Final dosing of the last patient concludes the Phase 3 study in people with Type 2 diabetes, event associated with a $10 million payment from Tonghua Dongbao to Adocia Phase 3 topline results...
► Artikel lesen
04.12.24ADOCIA SA: Number of Shares and Voting Rights of ADOCIA as of November 30th, 2024347Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or...
► Artikel lesen
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1